Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (221-230 of 418) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.
Nature Medicine|September 18, 2012
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanomaLawrence N Kwong, James C Costello, Huiyun Liu, et al.
Plos One|July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
Biorxiv : the Preprint Server for Biology|September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade TherapiesShiyou Wei, Kuang Du, Hongbin Lan, et al.
Cancer Research|May 6, 2017
Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human CancerDongmei Zhang, Gao Zhang, Xiaowen Hu, et al.
Pageof 42

Showing results (221-230 of 418) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.
Nature Medicine|September 18, 2012
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanomaLawrence N Kwong, James C Costello, Huiyun Liu, et al.
Plos One|July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
Biorxiv : the Preprint Server for Biology|September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade TherapiesShiyou Wei, Kuang Du, Hongbin Lan, et al.
Cancer Research|May 6, 2017
Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human CancerDongmei Zhang, Gao Zhang, Xiaowen Hu, et al.
Pageof 42